Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients
Clinical trial NCT03614234 · COMPLETED
Trial details
- NCT number
- NCT03614234
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-13
- Primary completion
- 2026-04-13
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.